Congenital candidiasis causes a variety of clinical features
ranging from a diffuse erythematous skin eruption with or without
vesicles and pustules to systemic disease where the lungs are
usually affected and the skin may or may not be affected.1,6–8
Although management guidelines have been published,1 due to
the rarity of the disease, firm recommendations are difficult to
make, since they are based on anecdotal experience. It has been
recognized, however, that full-term infants with congenital
candidiasis and skin involvement only, often have a benign clinical
course and probably do not require therapy, while in infants with
respiratory distress and clinical and laboratory signs of sepsis,
systemic antifungal therapy with amphotericin B is recommended.